Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05266872 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

Study acronym: LuxPARK
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 31, 2025 → Dec 31, 2027
See other at-risk trials from Luxembourg Institute of Health

Record History

  1. Notable Primary and study completion pushed from Dec 31, 2025 to Dec 31, 2027v5
  2. Notable Primary completion date: Dec 31, 2024 to Dec 31, 2025v4
  3. Minor 2 versions Re-verified since Mar 13, 2023, no change to tracked fieldsv2-v3
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Trial Details
NCT Number NCT05266872
Lead Sponsor Luxembourg Institute of Health
Collaborators: University of Luxembourg, Laboratoire National de Santé (LNS), Centre Hospitalier du Luxembourg
Conditions
(from sponsor)
Parkinson Disease
Related terms Parkinson Disease
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov